No title
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by an aggressive progression. Emerging evidence suggests that the tumor immune microenvironment (TIME), particularly tumor-infiltrating T cells, plays a key role in disease progression and prognosis for patients that are treated with modern combined immunotherapeutic regiments. Thus, the develop
